Avastin granted licence for use with ovarian cancer
Gilda Witte, CEO of Ovarian Cancer Action said: "We welcome the news that Avastin is now licensed for use in managing ovarian cancer. It provides thousands of women diagnosed with advanced ovarian cancer each year the hope of spending vital extra time with their families and loved ones.
Sadly too many women in the UK are diagnosed at a late stage of disease when the survival rates are considerably worse. Whilst Avastin provides new hope for prolonged life, we need to ensure more women are diagnosed at a an earlier stage to improve their chances of survival.
Ovarian Cancer Action continues to call on Government for measures to be built into clinical trials to ensure women don't suffer unnecessarily from their treatment. Women with ovarian cancer deserve a longer and better quality life."
Notes for Editors:
Ovarian Cancer Action is the UK's leading ovarian cancer charity, dedicated to improving survival rates for women with ovarian cancer. It funds innovative research into the disease at the Ovarian Cancer Action Research Centre; raises awareness of the symptoms with national awareness campaigns aimed at women and healthcare workers; and gives a voice to those affected by it, acting as an advocate with policymakers, healthcare professionals and scientists.
For further information please contact:
Tania Pearson at Ovarian Cancer Action at tpearson@ovarian.org.uk at 0300 456 4706.